Jammu and Kashmir LG Manoj Sinha addressed the 'IMMUNOCON-2026' conference, stressing the importance of translating scientific immunological knowledge into public health action. He urged scientists to focus on precision medicine, immuno-AI fusion, climate immunity, and accelerating translational research to combat infectious diseases and enhance healthcare delivery.
Jammu and Kashmir LG Manoj Sinha emphasised the critical need to translate scientific immunological knowledge into public health action. Speaking at the IMMUNOCON-2026 conference, he highlighted immunology's evolving role in healthcare, stressing continuous innovation and collaboration in areas like immuno-AI fusion, climate immunity, and translational medicine to combat infectious diseases and prepare for future global health threats.
Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon. Explore the leadership transition, strategy, and future plans.
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
'We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a particular disease area globally.'
'Working in collaboration is beneficial and more rewarding in the long run.' 'Competition may bring personal glory, but is very short lasting.' 'Work with people who are interested in working with you instead of competing with you.'
WHO has urged people at risk to keep up with their vaccinations with boosters.
The study describes a new blood test which pinpoints the immune system molecules called antibodies in infected individuals that specifically target a unique piece of the novel coronavirus SARS-CoV-2's spike protein.
Bharat Biotech is also looking at nasal vaccine as a booster dose as its scaling up capacity is very easy when compared with Covaxin, he added.
'However, we have seen weakness in our active pharmaceutical ingredients business.'
While Covishield supplies would meet the target of 500 mn doses between August and December, it looks like Covaxin would miss the target of 400 mn unless the partner sites of Bharat Biotech ramp up very rapidly, reports Sohini Das.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
Doctors claimed it is the first time that cases of gallbladder gangrene have been reported after recovery from COVID-19 infection.
A thirst for knowledge is essential for survival in this knowledge intensive field, but also important are skill sets like team work, multi-tasking and awareness of intellectual property rights.
The award was presented by Dr Martin Mackay, pesident Global R&D, Pfizer and Karun Rishi, president, USA-India Chamber of Commerce, at a function in Boston recently, according to a release by the chamber.
The Nagarkattis became interested in investigating the plant products for their anti-inflammatory properties because of their exposure to Ayurvedic medicine, which has argued that several plant products are effective against arthritis and other autoimmune diseases. The team plans to collaborate with scientists from India to test a large number of plant extracts for their anti-inflammatory properties and study their mode of action.
National Institute of Immunology invites applications for its PhD programme for the academic year 2007-2008.
'Scientific data has proven that masks can reduce COVID-91 transmission by 53 per cent...A booster dose of vaccine, even if it works, is just a temporary fix'
The Indian government and private firms have stepped up efforts to develop a vaccine to halt the spread of COVID-19 which has claimed over 3,700 lives with more than 1,25,000 cases in the country.
The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
The NTAGI has also stated that those having laboratory test proven SARS-CoV-2 illness should defer COVID-19 vaccination for six months after recovery, the sources said.
Novak Djokovic blamed "human error" on Wednesday for a mistake in his Australian immigration paperwork and apologised for breaking isolation for a photoshoot when he had COVID-19 last month.
'There is no data to show this virus is more deadlier.'
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India.
The Indian vaccine industry largely feels there are two ways in which vaccine innovation can be spurred - one, get a high price for the product and two, have the government buy a few hundred million doses of the product at a certain price.
As the global debate on booster shots gathers momentum, several scientists in New Delhi said the priority must be to ensure that more people are inoculated with at least their first jab.
He is the first MD Anderson scientist to receive the world's most preeminent award for outstanding discoveries in the fields of life sciences and medicine.
'In the likelihood that Omicron is circulating, you have a much greater chance of getting infected now, than you did during the Age of Delta.'
Scientists around the world, including in India, suggest it hasn't been tested properly given the time constraint and there may not be enough evidence to prove its efficacy.
The surgery will be performed by a team of experts constituted by AIIMS.
The Omicron variant carries 'concerning' mutations that may make it more transmissible and allow it to evade immunity, scientists said on Monday, stressing that the one certainty in the uncertainty of the many things unknown is this -- COVID is not a short-term crisis and vaccines are still a critical tool.
'We must not compromise with the standard, the quality. We don't need to be the first to launch a drug but what we need is a Made in India vaccine that the entire world can rely on'
'There are not enough RT-PCR tests and they take a long time to do in specialised centres. So the world is using RA tests for the same reason that India is using them, and with similar somewhat spuriously comforting rationale'
Why did the Chinese military take over the lab in Wuhan in end January? Did something go wrong? Claude Arpi glances at the mystery surrounding the origin of the coronavirus.
The Australian immunologist, who cautioned that the number of COVID-19 cases will rise in the coming days, said the earliest time frame for an effective vaccine 'going into large numbers of people' is nine to 12 months.
Some vaccine frontrunners are in advanced stages of trial and could hit the market by early next year, making the task of securing "last mile connectivity" and ensuring that nothing goes wrong before the shot is administered more urgent.
The impact of a 'dengue-COVID-19' season would entail two different diagnostic tests and extract a huge toll on patients too, each disease making the other more complicated to deal with and perhaps more fatal.
'This year, we know the virus. Last year we didn't know anything about it.' 'The best part is that for the Indian population there has been some amount of cross protection.'
As worries over India's COVID-19 spike mount -- the country added 75,809 cases on Tuesday to take its tally to 42,80,422 -- scientists are grappling with the pivotal issue of antibodies and trying to understand how they impact on the progression of the disease.
Addressing a press briefing, health ministry Joint Secretary Lav Agarwal said currently there are no approved therapies for COVID-19 and there is not enough evidence to claim that plasma therapy can be used for treatment of the disease.
